金河生物(002688) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥537,369,677.01, representing a 5.90% increase year-over-year, while the year-to-date revenue decreased by 3.86% to ¥1,569,845,460.39[5] - Net profit attributable to shareholders for Q3 2023 was ¥13,706,071.04, down 13.07% compared to the same period last year, with a year-to-date net profit of ¥103,065,407.57, an increase of 0.59%[5] - The basic and diluted earnings per share for Q3 2023 were both ¥0.0176, reflecting a decrease of 13.07% year-over-year, while the year-to-date figure was ¥0.1321, up 0.61%[5] - Total operating revenue for Q3 2023 was CNY 1,569,845,460.39, a decrease of 3.84% from CNY 1,632,853,473.87 in Q3 2022[38] - Net profit for Q3 2023 was CNY 113,857,343.09, compared to CNY 138,059,278.94 in Q3 2022, representing a decline of 17.5%[39] Assets and Liabilities - Total assets at the end of Q3 2023 reached ¥5,347,009,697.40, an increase of 18.68% compared to the end of the previous year[5] - Total liabilities increased to CNY 2,803,491,425.75 in Q3 2023 from CNY 2,083,219,030.19 in Q3 2022, marking a rise of 34.5%[36] - Current liabilities totaled CNY 2,163,636,212.43, up from CNY 1,664,636,415.15, indicating a growth of 29.99% year-over-year[36] - Non-current liabilities rose to CNY 639,855,213.32 from CNY 418,582,615.04, an increase of 52.7%[36] - The total assets as of January 1, 2023, were CNY 4,508,509,743.92, reflecting an increase of CNY 2,927,211.00 from the previous year[43] - The total liabilities as of January 1, 2023, were CNY 2,083,219,030.19, which increased by CNY 2,853,167.21 compared to the previous year[43] Cash Flow - The company reported a significant increase in cash flow from operating activities, with a year-to-date net cash flow of ¥170,291,814.82, down 0.55%[5] - The total cash inflow from operating activities was CNY 1,597,434,902.02, a decrease of 6.55% compared to CNY 1,709,541,407.33 in the previous period[40] - The net cash flow from operating activities was CNY 170,291,814.82, slightly down from CNY 171,225,026.36 in the same period last year[40] - Cash inflow from financing activities totaled CNY 1,690,472,443.19, an increase of 55.06% compared to CNY 1,090,068,501.54 in the previous year[41] - The net cash flow from financing activities was CNY 435,502,338.50, up from CNY 212,123,087.60 in the same period last year[41] - The total cash and cash equivalents at the end of the period amounted to CNY 555,875,886.69, down from CNY 613,646,726.64 at the end of the previous period[41] - The company reported a net cash outflow from investing activities of CNY 463,559,726.67, worsening from a net outflow of CNY 282,505,099.50 in the previous year[40] Investments and Acquisitions - The company’s investment in construction projects increased by ¥231,834,885.15, a growth of 77.08%, primarily for new pharmaceutical production facilities[12] - The company’s goodwill increased by ¥207,348,213.18, a rise of 69.37%, due to the acquisition of a 60% stake in Jilin Baishi Wanke Biotechnology Co., Ltd.[14] - Cash received from investment activities increased by ¥16,226,241.05, a growth of 791.52%, due to cash differences from the acquisition of 60% equity in Jilin Baishi Wanke[25] - Cash outflow from investment activities increased by ¥179,777,401.90, a rise of 59.52%, driven by ongoing construction projects and equipment payments[25] Shareholder Information - The largest shareholder, Inner Mongolia Jinhai Holdings Co., Ltd., holds 30.98% of the shares, with 241,758,670 shares pledged[32] - The total number of common stock shareholders at the end of the reporting period was 31,258[31] - The company completed the initial grant registration of its 2023 restricted stock incentive plan, awarding 21.37 million shares to 120 participants[33] Financial Management - Financial expenses rose by ¥31,498,050.61, an increase of 540.55%, primarily due to increased bank borrowings to meet operational funding needs[18] - Interest income increased by ¥3,043,977.92, a growth of 256.74%, attributed to the release of deposits and interest income from substantial dollar deposits held by subsidiary Famawei[18] - Investment income increased by ¥3,936,663.04, a 100.00% increase, as there were no similar losses from subsidiary Jinhe Environmental's previous year’s asset transfer[19] - Credit impairment losses increased by ¥2,324,360.40, a rise of 166.36%, due to extended aging of receivables from downstream customers affected by market conditions[19] - The company reported a significant increase in other payables, which rose to CNY 150,577,955.87 from CNY 24,777,398.48, indicating a potential shift in financial management strategy[36] Research and Development - Research and development expenses for Q3 2023 were CNY 45,876,398.38, down from CNY 56,106,293.73, a decrease of 18.3%[38] Other Information - The company has not undergone an audit for the third quarter report[45] - The report was released by the board of directors on October 27, 2023[46]